Rate Video

ASCO 2019 | Selinexor: an underappreciated MM development

Paul Richardson • 3 Jun 2019

ASCO 2019

Multiple Myeloma Dexamethasone Selinexor

Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the development of selinexor for the treatment of multiple myeloma at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

DETERMINATION: analysis of PFS benefit in different patient populations

Paul Richardson • 26 Aug 2022

Do results obtained in clinical trials translate accurately in real world practice?

Paul Richardson • 14 Jun 2018

What does the TOURMALINE-MM2 study tell us about the use of ixazomib in multiple myeloma?

Paul Richardson • 29 Mar 2017

A multiple myeloma patient story - a discussion between Vivien de Gunzburg and Paul Richardson

Paul Richardson et al. • 28 Apr 2016

Related Videos

A.R.R.O.W. study: carfilzomib dosing in frail MM patients

Maria-Victoria Mateos

Managing CRS in myeloma

Managing transplant patients during the COVID-19 pandemic

Christian Chabannon

DNA methyltransferase inhibitors: daratumumab enhancement for MM